{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:06:34Z","timestamp":1781622394714,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,6]],"date-time":"2022-02-06T00:00:00Z","timestamp":1644105600000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.euo.2020.11.011","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T07:55:30Z","timestamp":1609401330000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer"],"prefix":"10.1016","volume":"4","author":[{"given":"Stacy","family":"Loeb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veda N.","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2020.11.011_bib0005","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1200\/JCO.20.00046","article-title":"Implementation of GT for prostate cancer: Philadelphia Prostate Cancer Consensus Conference 2019","volume":"38","author":"Giri","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.6004\/jnccn.2019.7307","article-title":"Germline and somatic mutations in prostate cancer for the clinician","volume":"17","author":"Cheng","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.euo.2020.11.011_bib0015","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: prostate cancer (version 4.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.euo.2020.11.011_bib0020","unstructured":"National Comprehensive Cancer Network. NCCN guidelines: genetic\/familial high-risk assessment: breast, ovarian, and pancreatic (version 1.2020). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf."},{"key":"10.1016\/j.euo.2020.11.011_bib0025","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0030","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.11.011_bib0035","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1001\/jamaoncol.2016.5465","article-title":"Increase in prostate cancer distant metastases at diagnosis in the United States","volume":"3","author":"Hu","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0040","unstructured":"National Cancer Institute. Genetics of prostate cancer (PDQ\u00ae)\u2013health professional version. https:\/\/www.cancer.gov\/types\/prostate\/hp\/prostate-genetics-pdq."},{"key":"10.1016\/j.euo.2020.11.011_bib0045","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.11.011_bib0050","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.euo.2020.11.011_bib0055","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/pros.23739","article-title":"Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing","volume":"79","author":"Giri","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2020.11.011_bib0060","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamaoncol.2018.6760","article-title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","volume":"5","author":"Nicolosi","year":"2019","journal-title":"JAMA Oncol"},{"issue":"5 Suppl 2","key":"10.1016\/j.euo.2020.11.011_bib0065","first-page":"24","article-title":"Molecular insights into the germline for prostate cancer initiation, progression, and aggressiveness","volume":"26","author":"Pritchard","year":"2019","journal-title":"Can J Urol"},{"issue":"5 Suppl 2","key":"10.1016\/j.euo.2020.11.011_bib0070","first-page":"19","article-title":"Germline contributions to metastatic prostate cancer","volume":"26","author":"Cheng","year":"2019","journal-title":"Can J Urol"},{"key":"10.1016\/j.euo.2020.11.011_bib0075","article-title":"Inherited mutations in males undergoing multigene panel testing for prostate cancer \u2013 emerging implications for personalized prostate cancer genetic evaluation","volume":"1","author":"Giri","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0080","unstructured":"American Cancer Society. Cancer facts and figures 2020. https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2020.html."},{"key":"10.1016\/j.euo.2020.11.011_bib0085","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.eururo.2018.09.021","article-title":"Germline mutations in ATM and BRCA1\/2 are associated with grade reclassification in men on active surveillance for prostate cancer","volume":"75","author":"Carter","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.11.011_bib0090","author":"Mottet"},{"key":"10.1016\/j.euo.2020.11.011_bib0095","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk stratification, shared decision making, and care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2020.11.011_bib0100","author":"Lowrance"},{"key":"10.1016\/j.euo.2020.11.011_bib0105","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.eururo.2020.01.012","article-title":"Management of patients with advanced prostate cancer: report of the Advanced Prostate Cancer Consensus Conference 2019","volume":"77","author":"Gillessen","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.11.011_bib0110","article-title":"Genomic characterization of prostatic ductal adenocarcinoma identifies a high prevalence of DNA repair gene mutations","volume":"3","author":"Schweizer","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/pros.23484","article-title":"Intraductal\/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer","volume":"78","author":"Velho","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.euo.2020.11.011_bib0120","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1038\/s41436-020-0830-5","article-title":"Diagnosing hereditary cancer predisposition in men with prostate cancer","volume":"22","author":"Pritzlaff","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.euo.2020.11.011_bib0125","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 8","key":"10.1016\/j.euo.2020.11.011_bib0130","doi-asserted-by":"crossref","first-page":"viii272","DOI":"10.1093\/annonc\/mdy284.002","article-title":"Preliminary results from TRITON2: a phase II study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations","volume":"29","author":"Abida","year":"2018","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.euo.2020.11.011_bib0135","doi-asserted-by":"crossref","first-page":"V884","DOI":"10.1093\/annonc\/mdz394.043","article-title":"Pre-specified interim analysis of GALAHAD: a phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)","volume":"30","author":"Smith","year":"2019","journal-title":"Ann Oncol"},{"issue":"Suppl 5","key":"10.1016\/j.euo.2020.11.011_bib0140","first-page":"v325","article-title":"Preliminary results from the TRITON2 study of rucaparib in patients with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses","volume":"30","author":"Abida","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0145","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.euo.2020.11.011_bib0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000642","article-title":"A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone","volume":"8","author":"Graff","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2020.11.011_bib0155","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.euo.2020.11.011_bib0160","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1200\/JCO.2019.37.15_suppl.5045","article-title":"Interim results from a phase 2 study of olaparib (without ADT) in men with biochemically-recurrent prostate cancer after prostatectomy, with integrated biomarker analysis","volume":"37","author":"Antonarakis","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0165","doi-asserted-by":"crossref","DOI":"10.1177\/1758835919897537","article-title":"PARP inhibitor combinations in prostate cancer","volume":"12","author":"Pezaro","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0170","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/jnci\/djm005","article-title":"Prostate cancer progression and survival in BRCA2 mutation carriers","volume":"99","author":"Tryggvadottir","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2020.11.011_bib0175","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/sj.bjc.6605822","article-title":"Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis","volume":"103","author":"Edwards","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euo.2020.11.011_bib0180","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","article-title":"Germline BRCA mutations denote a clinicopathologic subset of prostate cancer","volume":"16","author":"Gallagher","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2020.11.011_bib0185","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/1940-6207.CAPR-10-0397","article-title":"Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families","volume":"4","author":"Thorne","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1016\/j.euo.2020.11.011_bib0190","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.eururo.2014.10.022","article-title":"Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer","volume":"68","author":"Castro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.11.011_bib0195","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2016.11.033","article-title":"Germline mutations in ATM and BRCA1\/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death","volume":"71","author":"Na","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2020.11.011_bib0200","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10689-010-9388-8","article-title":"Hereditary prostate cancer as a feature of Lynch syndrome","volume":"10","author":"Bauer","year":"2011","journal-title":"Fam Cancer"},{"key":"10.1016\/j.euo.2020.11.011_bib0205","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1200\/JCO.2012.44.1238","article-title":"Elevated risk of prostate cancer among men with Lynch syndrome","volume":"31","author":"Raymond","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0210","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"10.1016\/j.euo.2020.11.011_bib0215","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1056\/NEJMoa1110000","article-title":"Germline mutations in HOXB13 and prostate-cancer risk","volume":"366","author":"Ewing","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2020.11.011_bib0220","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s13277-013-1157-5","article-title":"G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis","volume":"35","author":"Huang","year":"2014","journal-title":"Tumour Biol"},{"key":"10.1016\/j.euo.2020.11.011_bib0225","unstructured":"National Comprehensive Cancer Network. Clinical guidelines in oncology (NCCN guidelines\u00ae): genetic\/familial high-risk assessment: colorectal (version 1.2020). www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf."},{"issue":"12","key":"10.1016\/j.euo.2020.11.011_bib0230","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1200\/OP.20.00431","article-title":"Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC","volume":"16","author":"Szymaniak","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.euo.2020.11.011_bib0235","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clgc.2019.04.013","article-title":"Germline Genetic testing in advanced prostate cancer; practices and barriers: survey results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium","volume":"17","author":"Paller","year":"2019","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2020.11.011_bib0240","doi-asserted-by":"crossref","first-page":"501.e15","DOI":"10.1016\/j.urolonc.2018.07.002","article-title":"Physician attitudes about genetic testing for localized prostate cancer: a national survey of radiation oncologists and urologists","volume":"36","author":"Kim","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2020.11.011_bib0245","article-title":"Knowledge and practice regarding prostate cancer germline testing among urologists: gaps to address for optimal implementation","volume":"25","author":"Loeb","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.euo.2020.11.011_bib0250","doi-asserted-by":"crossref","DOI":"10.5489\/cuaj.6779","article-title":"Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists","author":"Hotte","year":"2020","journal-title":"Can Urol Assoc J"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120302078?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931120302078?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:46:16Z","timestamp":1762875976000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931120302078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2588931120302078"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2020.11.011","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2020.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}